The value of multidetector-row computed tomography in lymph node staging of gastric cancer: a preliminary Vietnamese study.

INTRODUCTION: Gastric cancer (GC) is the fourth most common malignant disease in the world, following breast cancer, colorectal cancer, and lung cancer. This study aimed to evaluate the usefulness of multidetector-row computed tomography (MDCT) in identifying the metastatic lymph node of GC.
MATERIAL AND METHODS: A cross-sectional study was performed after receiving approval by the institutional review board. A total of 88 patients with GC, who underwent radical gastrectomy, were examined by MDCT. Categorical variables were compared using Fisher's exact test. The discriminating ability of lymph node size was determined according to an area under the receiver operating curve(AUROC) analysis, and the optimal cut-off point was determined.
RESULTS: The proportion of metastatic lymph node patients in the proximal group (32.3%) was significantly higher than that in the distal group (18.4%). T categorisation and lymph node sizes were significantly different between the non-metastatic lymph node and metastatic lymph node groups. The AUROC for lymph node size was 0.738, with an optimal cut-off point of 7.5 mm,producing a sensitivity of 71.5% and a specificity of 70.5%.
CONCLUSIONS: MDCT displayed medium accuracy for the determination of metastatic lymph nodes and N categorisation. Based on our findings, although MDCT is generally the first choice for preoperative assessments in GC patients, other diagnostic modalities should supplement MDCT in order to achieve more precise N staging.

Introduction

Gastric cancer (GC) is the fourth most common malignant disease in the world, following breast cancer, colorectal cancer, and lung cancer [1]. Although the incidence of GC has been decreasing, it remains the most prevalent form of cancer in Asian countries, including Vietnam [1, 2]. Radical surgical resection is a common curative treatment for GC. However, the mortality rate remains high, with a five-year survival rate of approximately 30–35% [3]. Surgical results depend on the GC stage at presentation, which includes the depth of tumour invasion and the extent of local lymph node and distant metastases. Therefore, determining the exact GC stage before surgery is essential for establishing suitable treatment plans. Multidetector-row computed tomography (MDCT) is the most commonly used modality for preoperative GC assessments. MDCT image can be usefully employed to determine tumour size and location (T staging) and to identify distant organ metastasis. However, the role of MDCT during the identification and categorisation of cancerous lymph nodes (N staging) remains controversial [4, 5]. The present study aimed to assess the role of MDCT in the staging and classification of lymph nodes during GC.

Material and methods

Study design and participants

A cross-sectional study of 88 patients was conducted in Hanoi, Vietnam, from September 2015 to October 2016. The participants were GC patients who had undergone radical gastrectomy at 108 Military Central Hospital in Hanoi. The inclusion criteria were as follows: 1) patients diagnosed with GC by gastroscopic biopsy; 2) patients naive to neoadjuvant chemo-radio-therapeutic treatment before surgery; and 3) patients with no history of allergy to iodine contrast agents. The exclusion criteria were as follows: 1) presenting with other cancers, in addition to GC; and/or 2) recurrent GC. All participants underwent MDCT examinations, using a unique protocol. The imaging findings were compared with histopathological results.

This study was approved by the Scientific Committee in Biomedical Research, 108 Military Central Hospital (Ref: 262/QĐ-V108, dated 10 Sep 2015). All patients in the study provided informed consent before collecting data, and all were informed of their complete right to withdraw from the study at any time, without threat or disadvantage.

Data collection

Data collection was performed by two experienced radiologists, who are the authors of the present manuscript. Data regarding the demographic and clinical characteristics of the patients were extracted from the participants’ medical records. The MDCT images were collected according to a unique protocol template.

MDCT protocol

MDCT was performed using a 16-detector-row computed tomography (CT) scanner (BRIVO CT 385, GE Health care, USA). The parameters were as follows: slice thickness 1 mm, rotation time 1 second, and pitch 1.75, 120 kVp, and 250 mAs. All patients were examined after fasting for at least eight hours and received approximately 500–1000 ml of warm water, orally, prior to the study. An intramuscular injection of 20 mg hyoscine butylbromide (Buscopan, Boehringer Ingelheim, Spain) was administered 10 minutes prior to scanning. Then, 100 ml iobitridol (Xenetix 300, Guerbet, France) was injected into the cubital vein, using an automated injector device, at a velocity of 3.0 ml/s. Arterial and venous phase images were acquired at 30 and 70 sec after the contrast injection, respectively [6, 7]. All patients were in a supine position, and the scan range was extended from the diaphragm to the pubic symphysis. After scanning, reconstructions were performed using multiplanar reformations (Fig. 1).

Fig. 1

Images of a 78-year-old man with well-differentiated adenocarcinoma, T3 stage. (A) Axial MDCT image and (B) reconstructed coronal MDCT image. The white arrows indicate the group 8 lymph nodes. The short diameter of the lymph node was 26 mm. This was proven metastatic lymph node by histopathological examination

MDCT image analysis

Two radiologists, with 15 and 20 years of experience and without knowledge of patient information, independently analysed the imaging data. The inter-observer agreement was excellent for all MDCT findings. Thus, the results of the first reader (first author) were used for all further analyses.

The collected lymph node data included the number, location, diameter of the short axis, and enhancement level. Primary tumour data were also recorded. To detect lymph nodes, the 1-mm-thick axial images were examined in cine-mode display. To measure the sizes of lymph nodes, both axial images and oblique multiplanar reformation images were used to identify the longest diameter of each lymph node in all three dimensions. The short diameter of the lymph node was measured perpendicular to the longest axis in the same image. The MDCT nodal groups were defined based on anatomic landmarks, and 16 groups were identified according to the Japanese Research Society for Gastric Cancer (JRSGC) guidelines [8]. Lymph nodes were considered metastatic if the short-axis diameter was greater than 8 mm. N categorisation was determined according to the 7th edition of the American Joint Committee on Cancer (AJCC) tumour, nodes, and metastases (TNM) staging system [9].

Surgery

All patients underwent radical gastrectomy and lymphadenectomy. The category of lymphadenectomy and the grouping of resected lymph nodes were decided by surgeons, based on the surgical findings. The same nodal grouping system was applied to all lymph nodes, regardless of whether they were detected during surgery and/or by MDCT. The surgeons defined and marked each lymph node detected by MDCT. Then, all resected lymph nodes were examined histopathologically, to confirm metastasis for each nodal group.

Statistical analysis

Statistical analyses were performed using SPSS version 22 (IBM Corp., New York, USA). Categorical variables were compared using Fisher’s exact test. The accuracy of MDCT for N categorisation was calculated by comparing the images with the histopathological findings. The ability to use lymph node size to determine metastasis was evaluated based on the area under the receiver operating characteristic curve (AUROC) analysis. The optimal cut-off point was identified based on the Youden index, which was then used to calculate the sensitivity, specificity, and accuracy of MDCT-based diagnoses. A p-value of < 0.05 was considered significant for all statistical analyses.

Results

According to Table 1, of the 1104 lymph nodes that were resected and examined histopathologically, 341 nodes (30.9%) were positive for metastasis. At MDCT, 464 nodes were detected. Of these, four nodes were determined histopathologically to be false positives and were excluded from the study. Of the 460 lymph nodes detected at MDCT, 206 nodes were considered metastatic nodes (size ≥ 8 mm).However, only 165 of these nodes were determined to be metastatic based on the histopathological analysis. The mean short-axis diameter of metastatic lymph nodes (10.10 ±5.31 mm; range 4–35 mm) was larger than that of non-metastatic lymph nodes (6.89 ±2.12 mm; 4–17 mm, p < 0.001).

Table 1

Numbers of lymph nodes detected by multidetector-row computed tomography (MDCT) and histopathological examinations, according to nodal group

Nodal group		Histopathological examination		MDCT examination
		Number of nodes detected	Number of metastatic nodes	Number of nodes detected	Metastatic nodes MDCT +	Metastatic nodes histopathology +
Proximal group	1	4	0 (0)	2 (50)	1	0 (0)
	2	9	3 (33.3)	1 (11.1)	0	0 (0)
	3	454	142 (31.3)	207 (45.6)	89	82 (39.6)
	4	120	20 (16.7)	50 (41.7)	16	8 (16)
	5	54	22 (40.7)	30 (55.6)	18	12(40)
	6	349	133 (38.1)	133 (38.1)	58	53 (39.8)
	1–6	990	320 (32.3)a	423 (42.7)b	182	155 (36.6)c
Distal group	7	8	1 (12.5)	2 (25)	1	0 (0)
	8	38	7 (18.4)	18 (47.4)	10	5 (27.8)
	9	7	5 (71.4)	3 (42.9)	3	2 (66.7)
	10	0	0	0	0	0
	11	0	0	0	0	0
	12	21	5 (23.8)	3 (14.3)	3	2 (66.7)
	13	35	3 (8.6)	10 (28.6)	7	1 (10)
	14	5	0 (0)	1 (20)	0	0 (0)
	15	0	0	0	0	0
	16	0	0	0	0	0
	7–16	114	21 (18.4)a	37 (32.5)b	24	10 (27)c
Total		1104	341 (30.9)	460 (41.7)	206	165 (35.9)

numbers in parentheses are the percentages of metastatic nodes relative to the total nodes detected by histopathological examination, p < 0.01; b numbers in parentheses are the percentages of total nodes detected by MDCT relative to the total nodes detected by histopathological examination, p < 0.05; c numbers in parentheses are the percentages of metastatic nodes detected by MDCT and confirmed by histopathological examination relative to the total number of nodes detected by MDCT, p > 0.05

Nodal group analysis showed that 990 lymph nodes were in the proximal group and 114 nodes were in the distal group. The proportion of metastatic lymph nodes in the proximal group (32.3%; 320/990) was significantly higher than that in the distal group (18.4%; 21/114). Approximately 94% of total metastatic lymph nodes were determined to be located in the proximal group, although both benign lymph nodes and metastatic lymph nodes were founded in all six nodal groups included in the proximal group. In contrast, metastatic lymph nodes were not founded in nodal groups 10, 11, 14, 15, and 16, in the distal group.

Of the 460 lymph nodes detected by MDCT, approximately 92% (423 nodes) were identified in the proximal group. The proportion of lymph nodes detected by MDCT in the proximal group was also higher than that in the distal group (42.7% vs. 32.5%, p < 0.05). Although the total number of metastatic lymph nodes identified in the proximal group was higher than that in the distal group, no significant difference in the percentage of identified metastatic nodes was found between groups (36.6% vs. 27%, p > 0.05).

Table 2 shows the numbers of resected lymph nodes, metastatic lymph nodes, and lymph nodes detected by MDCT, according to size. The majority of resected lymph nodes (72.3%) were small (< 8 mm). The proportion of MDCT-identified metastatic lymph nodes and the sensitivity with which MDCT detected lymph nodes increased as node sizes increased. Of 798 resected lymph nodes < 8 mm, only 193 nodes (24.5%) were determined to be metastatic, whereas 148 of 306 nodes (48.4%) ≥ 8 mm were determined to be metastatic, which represented a significant difference. The ability of MDCT to identify nodes < 8 mm (32.2%) was significantly reduced compared to that for nodes ≥ 8 mm (67.3%). Similarly, the proportion of metastatic lymph nodes < 8 mm (18.5%) detected by MDCT was significantly lower than the proportion ≥ 8 mm (57.3%). All lymph nodes > 20 mm were metastatic and correctly identified by MDCT.

Table 2

Numbers of lymph nodes detected by multidetector-row computed tomography (MDCT) and histopathological examination, according to sizes

Size (mm)	Histopathological examination		MDCT examination
	Number of nodes detected	Number of metastatic nodesa	Number of nodes detectedb	Number of metastatic nodesc
1	4	0 (0)	0 (0)	0
2	48	5 (10.4)	0 (0)	0
3	161	22 (13.7)	0 (0)	0
4	162	28 (17.3)	10 (6.2)	1 (10)
5	251	79 (31.5)	99 (39.8)	19 (19.2)
6	98	37 (37.8)	88 (89.8)	19 (21.6)
7	74	22 (29.7)	57 (77.0)	8 (14)
1–7	798	193 (24.5)	254 (32.2)	47 (18.5)
8	67	29 (43.3)	58 (86.6)	27 (46.6)
9	27	14 (51.9)	21 (77.8)	8 (38.1)
10	119	46 (38.7)	76 (63.9)	45 (59.2)
11	15	7 (46.7)	7 (46.7)	2 (28.6)
12	28	15 (53.6)	14 (50.0)	12 (85.7)
13	2	2 (100)	0 (0)	0
14	7	5 (71.4)	5 (71.4)	4 (80)
15	20	13 (65.0)	6 (30.0)	4 (66.7)
16	3	2 (66.7)	3 (100)	2 (66.7)
17	1	1 (100)	1 (100)	0 (0)
18	0	0 (0)	0 (0)	0
19	0	0 (0)	0 (0)	0
20	8	5 (62.5)	5 (62.5)	5 (100)
> 20	9	9 (100)	9 (100)	9 (100)
≥ 8	306	148 (48.4)	206 (67.3)	118 (57.3)
Total	1104	341 (30.9)	460 (41.7)	165 (35.9)

numbers in parentheses represent the percentages of metastatic nodes detected by histopathological examination relative to total nodes detected by histopathological examination; b numbers in parentheses represent the percentages of total nodes detected by MDCT relative to total nodes detected by histopathological examination; c numbers in parentheses represent the percentages of the metastatic nodes detected by MDCT relative to total nodes detected by MDCT

The value of MDCT for N staging is shown in Table 3. The sensitivity, specificity, and accuracy were N0: 51.4%, 90.6%, and 75%; N1: 81.3%, 75%, and 76.1%; N2: 58.8%, 77.5%, and 73.9%; and N3: 40%, 100%, and 86.4%, respectively. The overall accuracy of MDCT for N staging was 55.7%. The consistency between MDCT imaging and the postsurgical histopathologic results for N staging was medium, with a κ value of 0.521 (95% confidence interval [CI]: 0.393–0.649). MDCT both overestimated and underestimated N staging assessments, with 20.4% of assessments representing overestimates and 23.9% representing underestimates.

Table 3

N categorisation of gastric cancers, by multidetector-row computed tomography (MDCT) and histopathological examinations

MDCT categorisation	Histopathological categorisation				p-value
	N0	N1	N2	N3
N0	18	2	3	0	< 0.001
N1	11	13	4	3
N2	6	1	10	9
N3	0	0	0	8

Table 4 shows the relationships between patients’ characteristics and MDCT findings, according to N staging results. T staging results and lymph nodes size showed significant differences between the non-metastatic and metastatic lymph node groups. Of 14 patients in the T1 category, 13 patients were classified as N0 and one patient was N2. Of the 16 patients in the T2 category, the number of patients classified as N0, N1, N2, and N3 were 8, 4, 2, and 2, respectively. Of 58 patients in the T3 category, the number of patients classified as N0, N1, N2, and N3 were 14, 12, 14, and 18, respectively. These results showed that as tumour infiltration progressed, the ability to detect lymph node metastasis increased.

Table 4

Patient characteristics and multidetector-row computed tomography (MDCT) findings relative to N category

Characteristics (n)	N category				p-value
	N0	N1	N2	N3
Sex					0.074
Male (65)	25	11	10	19
Female (23)	20	5	7	1
Age					0.66
< 40 (2)	0	1	1	0
40–59 (27)	11	5	6	5
≥ 60 (59)	24	10	10	15
Tumour location					0.52
Upper third (3)	1	0	2	0
Middle third (29)	12	4	4	9
Lower third (53)	21	11	11	10
Total (3)	1	1	0	1
Tumour size					0.85
< 40 mm (49)	21	8	10	10
≥ 40 mm (39)	14	8	7	10
T category					0.003
T1a (4)	4	0	0	0
T1b (10)	9	0	1	0
T2 (16)	8	4	2	2
T3 (58)	14	12	14	18
Nodal group					0.24
Proximal (423)	268	155
Distal (37)	27	10
Lymph node size					< 0.001
< 8 (254)	207	47
≥ 8 (206)	88	118

Bolded p-values indicate significance

Figure 2 shows the AUROC results for the ability of lymph node size to discriminate between metastatic and non-metastatic lymph nodes, with an AUROC value of 0.738 and an optimal cut-off point of 7.5 mm. When applying this cut-off point, the sensitivity and specificity were 71.5% and 70.5%, respectively.

Fig. 2

Receiver operating characteristic curve indicates the sensitivity, specificity, and optimal cut-off value of lymph node size for the differentiation of metastatic lymph nodes

Discussion

Lymph node metastasis is among the most important prognostic factors in GC. The five-year survival rate of patients without lymph node metastasis can reach as high as 85–90% [5]. MDCT is the most common technique used for the preoperative determination of N categories in GC patients. However, the diagnostic abilities of MDCT have varied among studies conducted in different countries [10]. In the present study, the proportion of metastatic lymph nodes in the proximal group was higher than that in the distal group. The proportion of lymph nodes in the proximal group detected by MDCT was also higher than that in the distal group. Fukuya et al. found that the MDCT sensitivities for the detection of nodes in groups 3 and 5 were significantly higher and lower, respectively, relative to the overall sensitivity for the detection of lymph nodes, and none of the nodes in nodal group 12 were detected [11]. Jiang et al. found that the accuracies of MDCT for the diagnosis of metastatic lymph nodes in groups 2, 10, and 13 reached 98.9%, and the sensitivities for groups 2, 9, 10, and 13 were 100% [7]. In contrast, Kim et al. reported that MDCT showed relatively low accuracy and positive predictive values for the perigastric lymph nodes near the lesser or greater curvature (groups 3 and 4) but demonstrated higher accuracy and positive predictive values for the lymph node groups 1, 5, 6, 7, 8, 9, and 11 [6].

We found that the short-axis diameters of metastatic lymph nodes were larger than those of non-metastatic lymph nodes. The proportion of metastatic lymph nodes and the sensitivity of MDCT for the detection of lymph nodes increased as the node size increased. In a previous study by Fukuya et al., lymph nodes were positive for metastasis in 5.1% of nodes < 5 mm, 21.7% of nodes 5–9 mm, 23% of nodes 10–14 mm, and 82.6% of nodes > 14 mm [11]. Of 382 MDCT-detected lymph nodes, Morgagni et al. found that only 22.9% of 261 lymph nodes that were not radiologically detected were infiltrated, including 16% of nodes < 5 mm, 33% of nodes between 5 and 10 mm, and 63% of nodes between 15 and 20 mm [12]. Kim and Kim also revealed that the sizes of metastatic lymph nodes were significantly larger than those of non-metastatic lymph nodes. As lymph node sizes increased, the proportion of metastatic lymph nodes out of all detected lymph nodes increased [13]. All results showed that size was an important criterion for determining metastasis and could be used for differentiation by MDCT. In this study, the lymph nodes were detected by both axial and oblique multiplanar reformation images. We believe that these techniques are the best for achieving precise measurements and represent a meaningful contribution to the field.

The reported accuracy of MDCT has varied among previous studies. Jiang et al. reported an overall accuracy of 86.3% for N staging based on MDCT findings, and the consistency between MDCT images and pathological N staging results (except for N2) was good, with κ values ranging from 0.449 to 0.662 [7]. In a study by Yan et al., the sensitivity and specificity of MDCT for the preoperative prediction of metastatic lymph nodes in GC were 77.4% and 73.3%, respectively, whereas the sensitivity and specificity of MDCT for the preoperative prediction of N2 and N3 were 15.4% and 100%, respectively [14]. According to Kim et al., the overall accuracy of N staging by MDCT was 63.2%. Of 106 N0 cases, MDCT overestimated 11 cases (10.4%). Of the 65 cases categorised as N1 or higher, MDCT underestimated 48 cases (73.8%) and overestimated four cases (6.2%). Overall, MDCT had a sensitivity of 60.0%, a specificity of 89.6%, an accuracy of 78.4%, and a positive predictive value of 78.0% for detecting the presence of lymph node metastasis [6]. Luo et al. performed a meta-analysis that included 27 studies and 6519 subjects, to evaluate the value of MDCT for pre-operative lymph node staging [10]. The authors revealed that the value was variable, with sensitivities ranging from 17%, as reported by Ahn et al. [15], to 97%, as reported by Karakoyun et al. [16], and specificities ranging from 61%, as reported by Feng et al. [17] and Pan et al. [18], to 100%, as reported by Joo et al. [19]. The meta-analysis reported summary sensitivity, specificity, and AUROC values of 0.67 (95% CI, 0.56–0.77), 0.86 (95% CI, 0.81–0.90), and 0.86 (95% CI, 0.83–0.89), respectively, with mild heterogeneities. These results indicated that the ability of MDCT to determine preoperative lymph node staging in GC patients was limited due to low sensitivity

The criteria for defining metastatic lymph nodes using preoperative MDCT differed among previous studies. Most studies defined metastatic lymph nodes based on the short-axis diameter, with nodes considered to be metastatic if the short-axis diameter was larger than 10 mm [20], 8 mm [6, 21, 22], or 6 mm for perigastric lymph nodes, and larger than 8 mm for extraperigastric lymph nodes [14, 23]. In addition to size, central necrosis, strong enhancement, and clusters of three or more perilesional nodes were also considered to be indicators of local metastasis. In this study, a short-axis diameter larger than 8 mm was used to differentiate metastatic lymph nodes, which is similar to the criterion used by most studies. However, central necrosis and/or enhancement are only recognised in larger nodes. In the present study, using size as an independent standard, the AUROC value was 0.738, with an optimal cut-off point of 7.5 mm, resulting in a sensitivity and specificity of 71.5% and 70.5%, respectively. These results were similar to those reported by Yan et al. [14] (AUROC: 0.789, cut-off value: 0.585 cm, sensitivity: 80.2%, and specificity: 66.4%) and Bai et al. [20] (AUROC: 0.807, cut-off point: 6.0 mm, sensitivity: 75.8%, and specificity: 75.6%).

The N category also depends on tumour infiltration. In this study, only 7.1% of patients categorised as T1 had metastatic lymph nodes, whereas 75.9% of patients categorised as T3 had metastatic lymph nodes. As the tumour aggressiveness increased, the proportion of metastatic lymph nodes increased. Jiang et al. found that 100% of T1 patients, 95.7% of T2 patients, 44.5% of T3 patients, and 20.7% of T4 patients were classified as N0. The N3 classification was only identified in 18.5% of T3 patients and 48.3% of T4 patients [7]. Kwee et al. reviewed several articles and found that patients with T1 tumours have a low risk of lymph node metastasis [24]. Metastatic lymph nodes were found in 2.2% of patients classified as T1a and in 17.9% of patients classified as T1b GC [25]. In patients with T2 and T3 tumours, the proportions who presented with lymph node metastasis reached 44% and 64%, respectively [2].

This study had some limitations. First, only a small number of patients were evaluated. The results could change in a study examining a larger number of cases. Second, although we attempted to match the lymph nodes resected during surgery with those identified by MDCT, in some cases the surgeons were not able to determine exact matches, which could result in some correlation errors.

Conclusions

In conclusion, MDCT displayed medium accuracy for the preoperative determination of N staging and the detection of nodal group metastasis. Based on our findings, although MDCT is the first choice for the preoperative assessment of GC patients, other supplementary diagnostic modalities should be used, to achieve more precise N staging results.